OR WAIT null SECS
May 24, 2016.
Eli Lilly today stated it has the potential to launch 20 new products in the 10 years (2014 through 2023).
The company added that it could launch an average of two new indications or line extensions for already-approved products per year during that same time period.
In a presentation to the investment community, Lilly chairman John C. Lechleiter, Ph.D., said: "There are no guarantees given the nature of science and of our business; however, in looking at our recent launches and current pipeline, we believe we are in the midst of the most prolific period of new launches in our company's 140-year history."
Lilly's R&D efforts focus on five therapeutic areas. The four core areas are diabetes, oncology, immunology and neurodegeneration, and one emerging area is pain.
A live audio webcast of Lilly's presentation is available on the "Webcasts & Presentations" section of Lilly's investor website at http://investor.lilly.com/events.cfm